MREO
Price
$2.85
Change
-$0.02 (-0.70%)
Updated
Feb 21 closing price
Capitalization
442.16M
31 days until earnings call
XERS
Price
$3.75
Change
-$0.22 (-5.54%)
Updated
Feb 21 closing price
Capitalization
559.06M
10 days until earnings call
Ad is loading...

MREO vs XERS

Header iconMREO vs XERS Comparison
Open Charts MREO vs XERSBanner chart's image
Mereo BioPharma Group
Price$2.85
Change-$0.02 (-0.70%)
Volume$815.88K
Capitalization442.16M
Xeris Biopharma Holdings
Price$3.75
Change-$0.22 (-5.54%)
Volume$2.36M
Capitalization559.06M
MREO vs XERS Comparison Chart
Loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MREO vs. XERS commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MREO is a Hold and XERS is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (MREO: $2.85 vs. XERS: $3.75)
Brand notoriety: MREO and XERS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MREO: 74% vs. XERS: 149%
Market capitalization -- MREO: $442.16M vs. XERS: $559.06M
MREO [@Biotechnology] is valued at $442.16M. XERS’s [@Biotechnology] market capitalization is $559.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MREO’s FA Score shows that 1 FA rating(s) are green whileXERS’s FA Score has 0 green FA rating(s).

  • MREO’s FA Score: 1 green, 4 red.
  • XERS’s FA Score: 0 green, 5 red.
According to our system of comparison, both MREO and XERS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MREO’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 6 bullish TA indicator(s).

  • MREO’s TA Score: 4 bullish, 4 bearish.
  • XERS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, XERS is a better buy in the short-term than MREO.

Price Growth

MREO (@Biotechnology) experienced а -0.70% price change this week, while XERS (@Biotechnology) price change was +4.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

MREO is expected to report earnings on May 14, 2025.

XERS is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($559M) has a higher market cap than MREO($442M). XERS YTD gains are higher at: 10.619 vs. MREO (-18.571). XERS has higher annual earnings (EBITDA): -23.07M vs. MREO (-43.41M). MREO has more cash in the bank: 80.5M vs. XERS (69.4M). MREO has less debt than XERS: MREO (6.68M) vs XERS (271M). XERS has higher revenues than MREO: XERS (187M) vs MREO (1M).
MREOXERSMREO / XERS
Capitalization442M559M79%
EBITDA-43.41M-23.07M188%
Gain YTD-18.57110.619-175%
P/E RatioN/AN/A-
Revenue1M187M1%
Total Cash80.5M69.4M116%
Total Debt6.68M271M2%
FUNDAMENTALS RATINGS
MREO vs XERS: Fundamental Ratings
MREO
XERS
OUTLOOK RATING
1..100
8946
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
71100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8340
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (78) in the null industry is in the same range as XERS (93) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to XERS’s over the last 12 months.

MREO's Profit vs Risk Rating (71) in the null industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to XERS’s over the last 12 months.

MREO's SMR Rating (97) in the null industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that MREO’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (40) in the Pharmaceuticals Major industry is somewhat better than the same rating for MREO (83) in the null industry. This means that XERS’s stock grew somewhat faster than MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is significantly better than the same rating for XERS (100) in the Pharmaceuticals Major industry. This means that MREO’s stock grew significantly faster than XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MREOXERS
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 17 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
YASLX10.13-0.07
-0.69%
AMG Yacktman Special Opportunities Z
VTARX10.75-0.09
-0.83%
Virtus Tactical Allocation R6
STFGX121.18-1.35
-1.10%
State Farm Growth
ADOZX21.56-0.40
-1.82%
Alger Dynamic Opportunities Z
FZADX24.32-0.54
-2.17%
Fidelity Advisor Dividend Growth Z

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with TERN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then TERN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
-0.70%
TERN - MREO
39%
Loosely correlated
-3.03%
MDGL - MREO
37%
Loosely correlated
-4.22%
INZY - MREO
34%
Loosely correlated
-1.57%
TRDA - MREO
34%
Loosely correlated
-0.23%
XERS - MREO
34%
Loosely correlated
-5.54%
More

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with TRDA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
-5.54%
TRDA - XERS
43%
Loosely correlated
-0.23%
SCPH - XERS
40%
Loosely correlated
-3.27%
MGTX - XERS
39%
Loosely correlated
+6.88%
KROS - XERS
38%
Loosely correlated
-0.09%
RXRX - XERS
37%
Loosely correlated
-10.34%
More